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One of the bottlenecks for cell therapy development is the need to isolate 
specific cells, be it stem cells with specific differentiation fates, or specific 
white cells from a blood cell sort. However, the nature of the application 
means that the separation method should ideally be label-free and GMP-
compliant, as well as achieving appropriate levels of throughput and cell 
recovery. One emergent field in cell separation is dielectrophoresis, an 
electrostatic method that has the potential to meet this growing need. 
Recent commercial developments mean that for the first time, this tech-
nique will be more widely available to the cell therapy sector.
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SEPARATION AND EXPANSION 
TECHNOLOGIES
THE NEED FOR LABEL-FREE 
CELL SEPARATION
As limitations grow on developing 
pharmaceutical therapies to inter-
vene in diseases of cancer and aging, 
such as neurodegenerative disease, 
medicine is turning to alternative 
approaches to intervention. One of 
the growth areas of greatest impact 
in clinical research is in the use of 
cell therapies; the use of living cells 
to repair, replace and augment the 
existing body tissues [1]. This can 
take the form of neural stem cells se-
lected to replace missing or damaged 
tissue in Alzheimer’s or Parkinson’s 
disease [2]; or it can be used to treat 
disease by modifying specific cells, 
such as the use of lentivirus-aug-
mented T lymphocytes for CAR-T 
therapies, where altered immune 
cells are used to combat cancer by 
reprogramming them [3]. As the in-
terest in cellular therapeutics grow, 
so does the need for isolating cells of 
therapeutic importance. Stem cells 
can differentiate into multiple cell 
types, requiring a selection method 
to isolate the ones of interest; white 
blood cells are easily extracted us-
ing common clinical apheresis [4], 
but the T lymphocytes required for 
CAR-T must then be extracted from 
the other nucleated cells. 
Cell separation has been achieved 
by many methods since its first 
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demonstration in the early 1960s 
[5], but it is currently overwhelm-
ingly achieved by three methods, 
each of which occupies slightly over 
30% of the cell separation market 
globally [6]. The first of these is 
the density gradient method. Cells 
are placed in a centrifuge tube [7], 
density of which varies from top to 
bottom. Cells move in this gradient 
through the spin process, coming to 
rest at the level where the density 
of cell and medium are equal. This 
method is commonly used where 
there are significant physical differ-
ences between the cells in question; 
for example, its primary application 
is in the sorting of red and white 
blood cells. However, as such chang-
es correspond to significant differ-
ences between cells, it is less useful 
when separating stem cells from a 
common progenitor but with dif-
ferent differentiation fates, nor is it 
sufficiently sensitive to discriminate 
between subpopulations. However, 
it is the simplest and cheapest cell 
separation method, as well as offer-
ing the highest throughput; tens of 
billions of blood cells can be pro-
cessed in as little as 30 minutes.
The next two common cell sepa-
ration methods both employ the use 
of chemical labels to identify cells of 
interest; Fluorescent-Activated Cell 
Sorting (FACS) [8] and  Magnet-
ic-Activated Cell Sorting (MACS) 
[9]. FACS uses fluorescent labels 
to identify target cells, giving the 
technique its name. These labels can 
interact with antigens on the cell 
surface or within the cell interior; 
they may identify the presence of a 
particular large molecule, or could 
depend on a different physiological 
effect such as membrane potential 
(with fluorescence intensity depen-
dent on transmembrane voltage). 
Cells are then passed through a 
machine containing one or more 
lasers used to interrogate the cells; 
fired in droplets containing a single 
cell, the cells pass through the beam 
before being electrostatically sort-
ed into appropriate outlet streams. 
The final common method, MACS 
relies on discriminating between 
cells according to the presence or 
absence of specific antigens on the 
surface of the cells. Magnetic mi-
crobeads coated with antibodies 
raised against the surface marker are 
incubated, causing the beads to at-
tach to the cells of interest (or the 
other, non-interesting population). 
A magnet is then used to extract the 
cells containing the beads, allowing 
separation. 
These two methods share com-
mon characteristics; the most sig-
nificant is that they identify cells 
by attaching a label (fluorescent or 
magnetic) to a protein of interest, 
as a basis for separation. This is sig-
nificant, for a number of reasons. 
Firstly, the label will persist in the 
separated population, potentially 
limiting the uses (particularly clin-
ical) to which the separated popula-
tion can be put. Secondly, the cost 
of labels can be significant. Thirdly, 
incomplete labeling of the popula-
tion can lead to losses of target cells 
of up to 50% of the population 
[10,11]. Fourthly, there is a risk that 
the label will interfere chemically 
with the cells. Finally, the use of la-
bels adds a sample preparation step 
that adds time and complexity to 
the workflow. However, the meth-
ods also have advantages; whilst not 
as fast as centrifugation, MACS can 
process up to one billion cells in an 
hour, whilst FACS is limited to a 
few tens of millions of cells over 2–3 
hours including sample preparation 
time and setup, whilst FACS in par-
ticular is also good for pinpointing 
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very rare cells through the use of 
multiple dyes; MACS is ultimately 
limited to identifying cells by sur-
face markers alone. Consequently, 
these methods are of questionable 
application for cell therapeutic ap-
plications [12].
In order to address these limita-
tions, researchers have spent many 
years attempting to develop non-
label-based (more commonly, ‘la-
bel-free’) separation methods that 
offer the benefits of centrifugation 
techniques with the added benefit 
of a broader range of selectivities. 
In order to achieve this, separation 
strategies must be identified that 
exploit physical differences between 
the cells, since only the properties 
inherent in the cells (such as den-
sity) are available in the absence of 
additional labels [13]. However, to 
be meaningful, such an approach 
must also offer the advantages of 
MACS and FACS, such as high 
throughput. Label-free strategies 
also potentially lack the flexibility 
of high-throughput systems such as 
FACS, where cells are sorted regard-
less of density; label-free, different 
approaches are commonly taken for 
circumstances where large numbers 
of cells are required, or where a very 
small number are to be sorted from 
a much larger population. 
DEP FOR LABEL-FREE 
SEPARATION
Fundamentally, any separation 
method – particularly something 
that performs binary separation, 
rather than multi-population frac-
tionation – performs some form of 
physical interrogation on the cells; 
the response of the cells to that 
intervention determines whether 
they are in the ‘in’ or ‘out’ groups 
– a form of shibboleth. In label-free 
sorting, this typically involves ap-
plying an external force field, and 
the response of the cell to that 
force field determines the direc-
tion in which it moves. To con-
sider the example of gradient cen-
trifugation, a force (the centrifugal 
force) is applied to the cells, which 
then respond differently according 
to where they lie in the gradient 
field. These different responses to 
the force then allow the cells to be 
moved to different locations with-
in the tube, and subsequently sep-
arated. For label-free separation, 
it is necessary to identify ways in 
which the cells might physically 
be different between populations; 
examples typically include (but are 
not limited to) differences in cell 
size, mechanical compliance, and 
electromagnetic properties [13]. We 
can also classify separation methods 
according to whether they sort on 
a continuous or batch process; that 
is, whether solution containing cells 
to be separated is constantly intro-
duced to the separation chamber 
and the separated components de-
part the process without interrup-
tion, or whether a defined volume 
is processed in a single process, then 
removed and repeated. FACS is an 
example of the former (separation 
can occur for as long as there is flow 
to the device), whilst centrifugation 
is an example of the latter (a batch 
of cells is processed at one time in 
a centrifuge). This being the case, 
what is the most suitable approach 
for cell separation for therapeutic 
purposes? The key figure is the to-
tal number of cells to be separated. 
Where a separation technique is 
continuous, there is no upper limit 
before the device becomes saturat-
ed; instead, the limit is one of time 
– how long does the separation of a 
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usable number of cells take? Taking 
T-cell therapy as an example, we can 
consider separation on the ‘input’ 
and ‘output’ ends of the process. If 
we were to extract all of the white 
blood cells from a healthy patient 
by apheresis, we would be looking 
at a starting solution of 109-1010 
cells. From this, we need to extract 
perhaps 10% of the cells [14]. Cell 
numbers are smaller when grown 
in culture – a T175 flask at conflu-
ence contains perhaps 2x107 cells. 
This then defines the way forward; a 
viable label-free separation method 
needs to discriminate on the basis of 
physical differences within the cells 
at a rate suitable for the application 
at hand.
Other than density gradient 
methods, several strategies have 
been put forward for label-free sep-
aration at volume; few strategies 
have developed beyond laboratory 
proof-of-concept stage, and none is 
in widespread use. One of the most 
advanced is separation on the basis 
of different electrical properties, 
using a phenomenon called dielec-
trophoresis (DEP) [15]. Related to 
electrophoresis, a much more com-
monly understood technique in bi-
ological sciences, DEP does not use 
the intrinsic charge of the moieties 
to be separated (which can include 
proteins but which are more com-
monly cells), but instead interacts 
with the dipole (with positive and 
negative components) induced 
when suspended in an electric field. 
The induced electrical dipole has an 
orientation and magnitude that is 
dependent on the electrical proper-
ties of the cell at the frequency of the 
field. By using a non-uniform field 
– that is, one with a gradient – cells 
are be attracted toward, or repelled 
from, the electrodes generating the 
field depending on the orientation 
of the dipole with respect to the 
field. A mixture of cells with dif-
ferent properties may experience 
frequency windows where the cell 
types respond by moving in oppo-
site directions, causing physical sep-
aration that can then be exploited. 
Whilst earlier observations of 
particle movement had been made, 
it was Herbert A Pohl of Oklahoma 
State University who first analyzed 
the phenomenon in detail, giving it 
both its definition and name. After 
studying the effect on a range of par-
ticles including bacteria, cell separa-
tion by DEP was first demonstrated 
in 1966 [16], with the separation of 
live and dead yeast cells by Pohl and 
his student, Ira Hawk. Since then, 
a range of technologies have been 
developed to make the technology 
suitable for industrial and biologi-
cal applications. These have focused 
on improving throughput, speci-
ficity or providing features such as 
multiple separation outputs. Early 
systems used machined electrodes 
to generate the inhomogeneous 
electric fields required for DEP 
to work; however, limitations on 
electrode design and the relatively 
low field gradients precluded these 
devices from high throughput and 
selectivity. Technology moved for-
ward significantly in the late 1980s 
when the group of Ronald Pethig 
at the University College of North 
Wales at Bangor developed the first 
microengineered electrodes [17]. 
Using principles from the fabri-
cation of microelectronics, these 
electrodes featured sharply defined 
contours that allowed much larger 
gradients in electric field strength. 
Using their pioneering ‘interdigi-
tated, castellated’ electrodes etched 
into a thin film of gold across the 
bottom of a chamber and then 
flowing cells across these, the group 
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demonstrated separations of the or-
der of those achieved with FACS 
and MACS. The group demon-
strated the efficacy of the system 
in multiple applications, beginning 
with live and dead yeast [18], and 
progressing to cells of therapeutic 
use in 1994 by demonstrating the 
enrichment of CD34+ cells from 
bone marrow [19,20]. Others using 
the same technology subsequently 
showed the separation of circulating 
tumor cells from general leukocyte 
populations [21]. 
THE PATH TO 
COMMERCIALIZATION
Whilst this technology showed 
great potential, it was never devel-
oped commercially. In the following 
years, many variants of this separa-
tion technology were published, 
presenting multiple separation out-
puts [22], vertical electrodes [23] 
and more, and several cell types 
used; several excellent review can 
be found describing both technolo-
gy and applications elsewhere (e.g., 
[24]). However, this period did not 
see the advancement of DEP sep-
aration outside of engineering de-
partments; it could be argued that 
there was a disconnection between 
the technology providers and the 
ultimate end users. Nevertheless, 
a number of scientists in the bio-
medical field used DEP separators 
to show that the technology could 
be used to separate stem cells with 
different differentiation fates on the 
basis of differences in membrane 
capacitance, including stem cells of 
neural, adipose, stromal and skel-
etal origin [25–30]. Another work 
by the Gascoyne group at the MD 
Anderson Cancer Center on the 
characterization of cells showed 
how differences in cells could be ex-
ploited for separation, showing that 
T-cell properties differ sufficiently 
from other leukocytes to be poten-
tially separable by this method [31]. 
Whilst the development of DEP 
technology and applications has 
largely remained within academia, 
three platforms have emerged to 
bring DEP separation devices 
to reach market. Two offer high 
throughput, but are developed 
for very different applications; the 
third eschews throughput for pre-
cision. The first of these [32] was 
developed by American company 
Apocell, based on technology orig-
inally developed in the laboratory 
of Peter Gascoyne at the MD An-
derson Cancer Center in Houston, 
TX, and has thus far been devel-
oped specifically for the isolation of 
circulating tumor cells from white 
blood cells. This is a continuous 
process whereby a mixture of cells 
passes along the edge of a chamber. 
The mixture passes over DEP elec-
trodes that induce a repulsive force 
in normal white cells, but not the 
desired tumor cells. Those remain 
next to the channel wall, where they 
are extracted through a thin slit; the 
remained flow with the bulk me-
dium towards a waste outlet. The 
system is still highly specialized in 
its application but offers very high 
rates of selectivity whilst processing 
cells at rates of up to 5000 per sec-
ond. However, the platform is still 
expensive to purchase, on par with 
high-throughput flow cytometry.
The second DEP platform [33], 
only reaching market now, was de-
veloped at the University of Surrey, 
UK. Based on technology developed 
previously for high-speed cell anal-
ysis [34] and called the DEParator, 
the technology takes a different ap-
proach to that taken by Apocell. 
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Rather than aiming for very high 
selectivity (the ‘one in a million’ 
separations), the device uses high 
throughput and low cell loss to 
enrich populations rapidly, the in-
tention being that multiple passes 
through the separator allow the 
user to achieve high degrees of sep-
aration with minimal outlay. The 
device operates by pushing a mix-
ture (typically 10–15 ml) of cells 
through a chip containing 4-500 
‘wells’, each striped along the side 
with 12 electrodes. These generate 
fields that trap one population of 
cells whilst the other falls through 
and is collected; once this is fin-
ished, the field is removed and the 
trapped portion can be recovered. 
The whole process takes approxi-
mately 10–15 minutes, and both 
the ‘passed through’ and ‘trapped’ 
populations can then be re-sepa-
rated to further enrich the desired 
population. Cell losses are suffi-
ciently small (typically 2% per 
pass) for several passes to be used 
without losing the target cells. On 
the other hand, the cell numbers 
that can be processed by the de-
vice are significantly higher than 
can be performed by any process 
other than centrifugation – separa-
tion speeds in excel of 150,000 per 
second have been demonstrated, 
whilst total cell numbers approach 
one billion. Furthermore, the cells 
spend the entire process contained 
within a disposable container con-
taining the chip and pumping 
mechanism, meaning that there is 
no risk of cross-contamination, and 
hence that the system can be engi-
neered to meet Good Manufactur-
ing Practice standards for cell sep-
aration for therapeutic purposes. It 
is anticipated that the consumable 
would retail for under $25, whilst 
the base station containing the 
support electronics is likely to be 
comparable to a MACS device. It 
is anticipated that this system will 
reach market in 2018.
The third commercial system is 
the DEParray form Silicon Bio-
systems [35]. This differs from the 
other two systems in that separa-
tion does not occur on the basis 
of electrical properties, but instead 
by optical detection of physical 
characteristics (which may include 
markers, but could also use cell 
morphology). Instead, the technol-
ogy locks tens of thousands of cells 
into DEP-actuated ‘cages’, and 
then unlocks adjacent cages to al-
low the target cells to be ‘corralled’ 
into areas where they can be col-
lected. Aimed much more at iden-
tifying rare cells than at processing 
large numbers of cells, it neverthe-
less offers a different approach to 
DEP-actuated separation.
CONCLUSION
As technologies for cell therapies 
progress towards general use, there 
is a need to address potential bot-
tlenecks to production. There is 
a need to isolate patient cells in a 
manner that is faster, cheaper and 
more compatible with good manu-
facturing practice than are currently 
available. Whilst there is develop-
ment work yet to do, it is possible 
that DEP may step forward to fill 
this gap in the coming years.
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